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Abstract

Candidiasis, the yeast infection of the mouth, genitals, and blood can be fatal in
individuals who are immunocompromised. In humans, Candidiasis is most commonly caused by
the yeast, Candida albicans (C. albicans), but can also be caused by other Candida species .[1]
C. albicans demonstrates marked resistance towards Cu(II) but more sensitivity towards
Co(II) compounds, especially in mutants that lack the CaCRP1 and CaCUP1 gene that encodes
for the copper-transporting P-type ATPase and Metallothionein proteins, respectively.[2] Here, I
will describe the effects of Co(II) and Cu(II) metal based complexes that incorporate a bridging
pyrophosphate (PPi) moiety.
Currently, we are exploring potential mechanisms of copper resistance and cobalt
sensitivity in C. albicans. We hope that in doing so, we can deepen our understanding of the
nature of C. albicans sensitivity and shed more light on potential development of therapeutics.
The main focus of this report will focus on the relationship between Co(II) and Cu(II)
during in vitro assays of C. albicans clinical isolates to measure growth and metal retention in C.
albicans.

4

Executive Summary
Recent years have seen a rise in fungal infections due factors such as poor patient
adherence to long term treatment and the increasing number of patients with severe
immunosuppression. While life expectancy has increased by more than ten years, this has also
led to an increase in the number of fungal infections and subsequent antimicrobial resistance.
The rise in drug resistance is currently an issue of much concern in the public world health sector
and emphasizes the crucial need for developments of new classes of antimicrobial therapies.
Of current fungal infections, candidiasis will be the focus of our discussion. Commonly
caused by the opportunistic yeast, Candida albicans, candidiasis includes oropharyngeal/
esophageal, vulvovaginal, and invasive candidiasis which are infections of the mouth, genitals,
and blood. Candida infections are commonly treated by azole-class drugs such as first line
defense drugs, fluconazole and itronazole. However, the current trend in resistance to first- and
second-line defense therapies has led our lab to explore the use of metal-based compounds as
potential alternative antimicrobial therapeutics. We are particularly interested in the use of Co+2and Cu+2- pyrophosphate (PPi) bridged complexes.
We hypothesize that specificity for and efficacy against Candida albicans can be
achieved by using Co+2 and Cu+2 complexes featuring the PPi moiety. We also hypothesize that
C. albicans will demonstrate higher sensitivity towards pyrophosphate-incorporated Co+2 than to
Cu+2 complexes due to mechanisms associated with evolution of resistance.
The first aim of my project was to resynthesize and character Co+2 and Cu+2 complexes,
{[Co(phen)2]2(µ-P2O7)} (CoD) and {[Cu(phen)]2(µ-P2O7)} (CuD). My second aim was to work
in collaboration with Dr. Michael Cynamon at the Veterans Affair Hospital (Syracuse, NY) to
perform in vitro assays on C. albicans isolates and Saccharomyces cerevisiae. All in vitro assays
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were done in the Cynamon group’s Biosafety Level 3 (BSL 3) facility, thus allowing us to work
with Candida albicans, a BSL 2 organism. My third aim was to perform in vitro assays of
mutant C. albicans strains, KC643 WT, KC2 WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ,
and KC12 cup1Δ which were kindly donated to us by Dr. Daniel Kornitzer, Technion-Israel
Institute of Technology, Israel. These mutant strains lack the gene required to synthesize
metallothionein (CaCUP1 gene) and the gene responsible of the P-type ATPase transporter
protein (CaCRP1 gene). My third goal is to perform Inductively Coupled Plasma Atomic
Emission Spectroscopy (ICP-AES) to measure metal retention in these organisms.
Once CoD and CuD were synthesized, in vitro assays consisted of microtiter assays that
determined the minimum inhibitory concentrations (MIC) in µg/mL concentrations. MuellerHinton broth (MHB) was used for S. cerevisiae. S. cerevisiae contains two copper import
transporters, Ctr1 and Ctr3, and was used as a quality control assay.
RPMI media was initially used during the in vitro assays because it was approved by the
Clinical and Laboratory Standard Institute (CLSI). Strains tested in RPMI were isolate #1,
KC643 WT, and KC24 cup1Δ/crp1Δ. All strains except for S. cerevisiae were also tested in YPD
media with uridine (KC12 cup1Δ and KC2 WT) and without (KC643 WT, KC24 cup1Δ/crp1Δ,
KC6 crp1Δ, and KC7 crp1Δ).
In RPMI media, isolate #1 and KC643 demonstrated higher sensitivity towards CoD than
towards CuD. Meanwhile, mutant, cup1Δ/crp1Δ, exhibited greater sensitivity towards CuD than
to CoD. This aligned with our expectations because the mutant lacked both genes responsible for
sequestering or effluxing copper ions and Co+2 should therefore be more active. In YPD media,
the same trend is observed again. MIC values of the remaining mutants, cup1Δ and crp1Δ, shows
that the CuD complex has higher activity than the CoD. Interestingly, crp1Δ is more sensitive
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towards CuD than was cup1Δ. This finding further suggests that the copper extrusion pump plays
a large role than the copper binding metallothionein in copper resistance. The double gene
knockout mutant, cup1Δ/crp1Δ, has the lowest MIC value of all the strains, suggesting that both
types of resistant mechanism takes part in lowering intracellular copper toxicity.
It should also be noted that all isolates grown in YPD media showed higher growth than
when grown in RPMI and CoD is significantly less active. A likely explanation is that the YPD
media contain unspecified metal chelators that diminishes the cytotoxic affect of CoD and CuD.
Varying the media emphasizes the importance of these the types of conditions in which these
organisms thrive. C. albicans are found in the mammalian digestive tracts where copper
concentrations are naturally high. While copper is an essential cofactor at low concentrations, it
becomes toxic at higher concentrations. Thus, C. albicans must have adapted to its ecological
niche to survive. In turn, C. albicans is not naturally exposed to toxic levels of cobalt metals in
its environment. Therefore, it has not had to opportunity to evolve mechanisms of cobalt
resistance.
To help explain the possible chelating effect of YPD media, future work includes
performing assays in MHB where extracellular metal binding is not observed. Finally, ICP-AES
assays will be performed to further understand the behavior of intracellular copper and cobalt
metals.
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Introduction
1.0) Hypothesis and Specific Aims
We hypothesize that specificity for and efficacy against C. albicans can be achieved by
using Co(II) and Cu(II) complexes featuring a pyrophosphate (PPi) moiety. We also hypothesize
that C. albicans will demonstrate higher sensitivity towards pyrophosphate-incorporated Co(II)
complexes as compared to the copper analogues through mechanisms associated with evolution
of resistance.
My first aim was to synthesize and characterize the Co(II) and Cu(II) complexes that
incorporated pyrophosphate. My second aim was to perform in vitro testing of these complexes
against Candida albicans, Candida krusei, Candida tropicalis, and Saccharomyces cerevisiae.
My final aim was to perform in vitro assays on single and double gene knockout strains of C.
albicans: KC643 WT, KC2 WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ, and KC12
cup1Δ.

1.1) Overview of Candidiasis[3]
Candidiasis, colloquially known as “yeast infection”, is a type of fungal infection that
occurs due to an imbalance of microorganisms at a particular location on the host and is most
prevalent in the United States. Usually caused by the opportunistic yeast, Candida albicans of
the Candida genus. This type of mycosis causes severe diseases in immunocompromised
individuals which can be fatal. Oropharyngeal candidiasis, also known as ‘thrush’, is marked by
the distinctive whitening of the tongue due to yeast overgrowth. Thrush is common in people
undergoing immunosuppressive therapy for cancer, patients with HIV/AIDS, after antimicrobial
therapy, or those receiving immune suppressive therapy after organ transplantation. C. albicans
is also the pathogen involved in vaginal yeast infections.
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Infections are diagnosed through either a microscopic examination or culturing a sample
from the patient. During microscopic examinations, the affected area is swabbed or scraped and
treated with potassium hydroxide (KOH). KOH dissolves the skin cells, leaving just C. albicans
to be visualized and examined. In the culturing method, the infected area is swabbed, streaked
onto a culture medium, incubated at 37 ˚C for several days, and the colonies are then examined.
A C. albicans colony is round, smooth, and white.
C. albicans is present in healthy humans, especially in the oral and intestinal flora, and
are in constant competition with other microorganisms for a particular location on the host. Until
an environmental imbalance occurs, C. albicans lives with other organisms in a commensal
relationship. An imbalance can be caused by stressors such as changes in pH or hormones,
oftentimes allowing C. albicans to outcompete the other organisms and overpopulate, leading to
disease.

1.4) Candida albicans and Treatment[4]
There are five main antifungal drug classes, each with its own targets. For example,
fluorinated pyrimidine analogs (5-FC) target the synthesis of RNA and DNA by interfering with
DNA replication. Polyene drugs, Nystatin and Amphotericin B (AMB), have heterocyclic
moieties that allow them to insert into the lipid bilayers of C. albican’s, increasing the cell’s
permeability by binding to ergosterol, and forming pores. Evidence shows that polyenes cause
oxidative damage and permit the efflux of cations, leading to cell death.
Unlike polyenes, azoles are fungistatic meaning that growth is inhibited, and the
organism is not killed. Fluconazole (Flu) is the azole first line of defense against C. albicans
infections and interferes with sterol biosynthesis by inhibiting lanosterol demethylase, a key
enzyme involved in ergosterol synthesis. Levels of ergosterol are depleted, which decreases

13

membrane integrity decreases and increases membrane permeability leading to fungal growth
inhibition.
Unlike earlier azole drugs such as ketoconazole, the synthetic triazole fluconazole offers
several advantages such as increased solubility, longer plasma half-life, and improved
pharmacokinetic properties.
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Need for New Drug Development to Combat Drug Resistance
2.0) Rise in Drug Resistance
The increase in drug-, multidrug-, and extensively drug resistant bacteria and yeast
compromises the effectiveness of existing antibiotics and antifungal treatment. In recent years,
there has been little effort in developing new classes of broth drugs. The resistance to current
treatments emphasizes the crucial need for new drug development, unfortunately, there are
relatively few new antibacterial compounds undergoing development, and few new classes of
antibacterial and antifungal drug therapy has been introduced to the market in the past three
decades.[5] The absence of new classes of drugs highlights the difficulties in discovering and
clinically testing new therapeutic agents.[6]
Avenues of approach include biogenesis and examining genes thought to be directly
involved in regulatory enzymes.[9] Researchers have also attempted to bypass bacteria such as M.
tuberculosis’s ability to adapt by developing new analogues of established drugs and screening
the compounds for activity using in vitro whole cell assays. As a result, private and public
research groups focus on finding new targets for potential antibiotic compounds. However, many
current treatments share similar or the same cellular targets, resulting in cross-resistance.[9]

2.1) Drug Resistance in Candidiasis [1,6,7]
Despite promising results from front line drugs, recent studies show that prolonged
fluconazole treatment resulted in treatment failures and C. albicans eventually develops a higher
resistance. It is possible that fluconazole is either not being retained (cellular uptake or efflux) or
that the drug target (14α-sterol demethylase) has changed. It is also possible that the membrane
composition has been altered and permeability towards fluconazole has decreased.
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Recent studies found that at high fluconazole concentrations, the rate of accumulation
plateaus, suggesting that the drug enters by facilitated diffusion. Additionally, there are two
genes, BENr and the CDR1 which encodes for proteins implicated in drug resistance and ATPbinding cassette-type transporter, respectively. Studies have also found that C. albicans isolates
that are resistant to fluconazole also expressed high levels of BENr, while isolates that are
resistant towards other azoles are possibly associated with elevated levels of CDR1 expression.
While increases in CDR1 and BENr levels do not necessarily lead to increased levels of their
products in in vitro systems, there is indirect evidence that Cdr1 and Benr multidrug transporters
in C. albicans use azoles as substrates in drug efflux. It is also plausible that elevated levels of
Benr and Cdr1 proteins interfere with systems that are directly involved with multidrug
resistance. If so, this regulatory function would follow recent evidence that suggest different
efflux systems are working together to form drug resistance mechanisms.

2.2) Unusual Resistance of Candida albicans to Copper
Interestingly, C. albicans has a high level resistance to elevated concentrations of copper,
especially when compared to Saccharomyces cerevisiae, and previous gene disruption studies
indicate that the copper-transporting P-type ATPase, coded by CaCRP1, is largely responsible
for this unusual resistance. A second gene, CaCUP1 which codes for metallothionein, has also
been implicated in copper resistance by functioning in residual copper binding. Under acidic,
anaerobic conditions the function of CaCRP1 is crucial for survival, even in very low
concentrations of copper.[1]
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2.3) Metallotherapeutics: New Generation of Alternative Drugs[6]
Despite roadblocks in finding new treatments for various forms of infectious diseases, a
growing area in drug discovery is bioinorganic chemistry. While metal-based therapeutics make
up a small percentage of available drugs, utilizing metals in drug delivery offers numerous
advantages over organic-based drugs. To begin, metals are cationic which allows them to attract
towards the negatively charged yeast cell membranes while also maintaining the metal
center(s)’s 3D geometry and ligand arrangements. Metals can also be active in their inert,
reactive, and biotransformational forms and metal complexes can even be active in fragmented
parts. Thus, metallopharmaceutical complexes offer varying redox states, extensive geometrical
diversity, and a great sum effect of metal-ligand interactions.

2.4) Existing Applications of Metals in Medicinal Chemistry[8]
After the breakthrough discovery of cisplatin, metal medicinal chemistry has become a
point of interest with a rise in effective compounds used in treatments against diseases such as
cancer, diabetes, and rheumatoid arthritis (RA).
Discovered by accident, cisplatin was the first metal-based agent to be used effectively
worldwide. A Pt(II)-based square planar compound, cisplatin can be administered alone or in
combination with other drugs to treat various types of cancers such as ovarian, lung, and bladder.
Cisplatin remains the ‘gold-standard’ despite the rise of second- and third-line Pt(II) analogues
such as carboplatin and oxaliplatin.
In treating diabetes, vanadyl complexes uses V+4 and V+5 to mimic insulin behavior by
oxidizing glucose in adipocytes and reducing blood glucose levels. Currently,
bis(ethylmaltolato)oxovanadium(IV), “BEOV”, is undergoing phase II clinical trials and is
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orally administered. Results show that patients treated with BEOV have a 15% decrease in blood
glucose levels relative to levels before the trials.
Aside from vanadium and platinum compounds, gold has two oxidation states that are
found in biological conditions; Au+ and Au+3, and forms drugs, myochrysine, solganol,
sanochrysine, and auranofin that are used to treat rheumatoid arthritis. Of these compounds, only
myochrysine, solganol, and sanochryine are soluble and are thus injected into patients while
auranofin is administered orally. Gold functions by targeting proteins and small molecules with
thiols or thioether functional groups and by saturating throughout the body, accumulating most at
sites of inflammation.

2.5) Efficacy of Inorganic Pyrophosphate Complexes[9]
We wanted to synthesize neutral dinuclear divalent compounds by using pyrophosphate
as the hydrophilic core. In addition to pyrophosphate, the metal centers would be chelated to
aromatic ‘capping’ ligands to create a hydrophobic component. Pyrophosphates also serve as
excellent ‘bridging’ ligands due to their level of protonation on the ligand species.
Pyrophosphate is a diphosphatetra-anion ([O3P-O-PO3]4-) and plays an important role in
bioenergetics processes. Found ubiquitously in nature the –P-O-P— moiety is a major form of
energy bond that circulates throughout living cells. Compounds with pyrophosphate have been
studied extensively, especially for their roles in coordination chemistry with possible
applications as treatment against infectious diseases. However, only 33 metallo-pyrophosphate
complexes have been properly characterized and reported to date, and of these compounds, only
18 complexes incorporate pyrophosphate as a bridging construct.
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Despite the modest numbers in pyrophosphate complexes, PPi coordination chemistry
has garnered much attention, specifically for their roles as potential drugs/prodrugs. More
recently, research from Doyle et al. and Bose et al. have contributed to interest revolving around
these pyrophosphate complexes as potential antitumor agents.[11,12] Work in these two labs show
that pyrophosphate systems involving Pt(I)/Pt(IV) or dimeric Co(II)/Ni(II)/Cu(II) demonstrated
extraordinary toxicity in drug-resistant cancer cell lines. The concentration of Pt-based
pyrophosphate compounds of the Bose group at which 50% of cisplatin/carboplatin-resistant
A2780/C30 cancer cell line was inhibited (IC50 value) was approximated half that of the required
cisplatin concentration. These complexes showed little DNA binding, suggesting that
pyrophosphate complexes to be potential alternative anticancer agents.[10]
Research performed in our lab utilizes and examines the added cytotoxicity of 1,10phenanthroline (phen) in dimeric compounds, {[Co(phen)2]2(μ-P2O7)} (CoD) and
{[Cu(phen)]2(μ-P2O7)} (CuD). These compounds appear to have unusually high toxicity against
Adriamycin-resistant A2780/AD cell line within the time dependent nano- and pico-molar
toxicity range. Meanwhile, cisplatin control has an inhibitory concentration of 11µM. The
overall toxicity is the sum of DNA interactions via binding or intercalation, oxidative stress, and
topoisomerase I inhibition. Internationalization of these complexes remains relatively unclear,
but a possibility is hydrolysis of the pyrophosphate upon entering and activation.[12]
The extraordinary degree of antineoplastic activity of CoD and CuD has led the Doyle
group to consider them as possible antibacterial therapeutics.
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Materials and Methods
3.0) Materials
Candida albicans ATCC 90028 and Saccharomyces cerevisiae were purchased from the
American Type Culture Collection (Manassas, VA) and were used as quality control strains.
Additional isolates were obtained from the Clinical Microbiology Laboratory, SUNY Upstate
Medical Center in Syracuse, NY Candida albicans #1 and C. albicans strains: KC643 WT, KC2
WT, KC6 crp1Δ, KC7 crp1Δ, KC24 cup1Δ/crp1Δ, and KC12 cup1Δ were kindly donated to us
by Dr. Daniel Kornitzer, Technion-Israel Institute of Technology, Israel.
Susceptibility tests were performed on the isolates according to the Clinical and
Laboratory Standard Institute (CLSI) document M27-A3 (Institute 2008). RPMI 1640 from
Hyclone Laboratories in Logan, UT was buffered at pH=7 with MOPS, 0.165 M. The control
drug, fluconazole (Sigma, St. Louis, MO) was made at 25.6 µg/mL in dimethyl sulfoxide.
Finally, cell turbidity was determined by a Klett colorimeter.

3.1) Synthesis {[Co(phen)2]2(µ-P2O7)} (CoD)
CoSO4 hexahydrate (0.5622g, 2 mmol) was dissolved in 15 mL of deionized H2O
resulting in a pale pink solution. Solid 1,10-phenanthroline (0.7208 g, 4 mmol) was next added
to the solution and allowed to fully dissolve before adding 5mL of aqueous tetrasodium
pyrophosphate (0.1659 g, 1 mmol) for a 2:4:1 ratio. The mixture was allowed to stir until a solid
pale pink solution with pink precipitate formed. The supernatant and precipitate were separated
via centrifugation and the supernatant was filtered for crystallization while the precipitate was
dried. Crystallization was conducted through slow evaporation in 25 mL glass beakers, resulting
in red-pink crystals after ca. 3-4 days. Crystals were also obtained through liquid-liquid
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diffusion. This was achieved by dissolving dried precipitate in water and minimal methanol.
Crystals formed in about 2-3 days. C54H56Co2N8O13P2 (1204.87): calculated. C 53.9, H 4.70, N
9.30; found C 53.8, H 4.69, N 9.31. FTIR (KBr): = 1625 (w), 1516 (s), 1497 (s), 1424 (s), 1342
(s), 1180 (sh), 1103 (br), 1021 (s), 906 (m), 849 (s), 725 (s), 566 (w) cm–1.

3.2) Synthesis of [Cu(phen)]2(μ-P2O7) (CuD)
CuD was synthesized in a similar procedure as the synthesis of CoD. First, CuCl (0.2689
g, 2 mmol) was dissolved in in 15 mL of deionized water to create a faint blue solution that was
free of precipitates. Next, solid 1,10-phenanthroline (0.3604 g, 2 mmol) was added to the first
solution. Finally, 5 mL of aqueous tetrasodium pyrophosphate (0.1659 g, 1 mmol) was added to
the solution for a final volume of 20 mL and yielded blue solution with no precipitate. The
solution was centrifuged at 4000 rpm for 10 minutes and the supernatant filtered out and
crystallized via ambient conditions for approximately 3 days. FTIR (KBr): = 1625 (w), 1516 (s),
1497 (s), 1424 (s), 1342 (s), 1180 (sh), 1103 (br), 1021 (s), 906 (m), 849 (s), 725 (s), 566 (w)
cm–1.

3.3) Preparation of Antifungal Agents
A dry stock solution of fluconazole was prepared in DMSO for a final concentration of
25.6 µg/mL The CoD drug solution was prepared by dissolving 10 mg of CoD in 10mL of
MeOH for a 1000 µg /1mL concentration. Additional CoD drug solutions were prepared at a
final concentration of 2000 µg /1mL and 5000 µg /1mL in 10% MeOH. Two CuD drug solutions
were prepared as well. The first was performed by adding10 mL of water to 10 mg of CoD (1000
µg/mL) and the solution was placed in an oil bath at 80 ˚C overnight or until fully dissolved. The
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second CoD solution was also dissolved in an oil bath, but this time the concentration was 20 mg
of CoD in 10 mL of water (2000 µg/mL). All of the solutions were filter-sterilized before using
in the in vitro assays. A methanol control was also used.

3.4) Determining MICs and CFU of Antifungal Agents
Saccharomyces cerevisiae was cultured and tested in Mueller Hinton Broth (MHB).
Candida albicans isolates (ATCC 90028, isolate #1, KC643 WT, KC2 WT, KC6 crp1Δ, KC7
crp1Δ, KC24 cup1Δ/crp1Δ, and KC12 cup1Δ) were cultured in 10 mL of media and incubated
overnight. RPMI-MOPS was initially used for C. albicans ATCC 90028, isolate #1, KC643 WT,
and KC24 cup1Δ/crp1Δ. YPD(-) uridine media was used for KC643 WT, KC6 crp1Δ, and KC7
crp1Δ. The C. albicans KC643 is the wildtype strain for the KC6 crp1Δ and KC7 crp1Δ gene
knockout mutants. KC2 is the wildtype strain of the cup1Δ mutant, KC12. The KC24 cup1Δ
/crp1Δ mutant is missing both CaCUP1 and CaCRP1 genes.
The drugs were prepared at four times the maximum concentration tested and 50 µL of
each drug stock solution was added respectively to the first well and serially diluted two-fold,
until the last well in which no drug was added to serve as a positive growth control. To prepare
fungal isolates, overnight cultures were diluted to a final concentration of approximately 5 x 105
CFU/mL in the respective broth. The actual inoculums were measured by plating and counting
CFU on the respective agar after 1:10000 serial dilution in saline with 0.05% Tween 80. The
agar plates were incubated for 2-4 days at 37 °C. The microtiter plates were covered with
SealPlate adhesive film (Excel Scientific, Wrightwood, CA) and incubated at 37 °C for the same
time period as the respective agar plates. The MIC was defined as the lowest concentration of
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antifungal agent yielding no visible turbidity. Each isolate was tested in at least one triplicate
and a known antifungal was used as a positive control.
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Results and Discussion
4.0) Synthesis and Characterization of Compounds CoD and CuD
The CoD compound was synthesized from an aqueous suspension of heptahydrate cobalt
(II) sulfate, phen, and tetrasodium pyrophosphate in a 2:4:1 stoichiometric ratio, resulting in a
pale pink solution with pink precipitate. Slow crystallization yielded pink-red crystalline blocks
after allowing to supernatant to evaporate at room temperature. The crystals were separated from
the remaining mother liquor, dried, and characterized by infrared spectroscopy (IR), elemental
analysis, and ultraviolet-visible spectroscopy. Meanwhile, the Cu(II) analog was synthesized in a
similar manner, but this time with a 2:2:1 stoichiometric ratio. The IR spectrum showed
characteristic [P—O—P] stretches at approximately 1103 and 840 cm-1 with shoulders at
approximately 1164 and 1021 cm-1. The presence of a phenanthroline ring was indicated by
bands near 1517 and 1426 cm-1. Water molecules that are shown by the broad band at
approximately 3400 cm-1 (figure 1).
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Figure 1. (a) Infrared spectrum of CoD (b) Infrared spectrum of CuD.

1500

1000

500

24

4.1) Crystal Structures of CoD and CuD
Single crystal X-ray diffraction
studies of compounds CoD and CuD (see
figure 2) show neutral species with binuclear
cobalt(II) and copper(II) centers
(respectively) and each metal center is
chelated to 1,10-phenanthroline rings: two
ligated to each cobalt(II) and one ligated to

(a)

copper(II) ions. Additionally, each metal center is
bridged by the hydrophilic pyrophosphate moiety
which forms a bis-bidentate structure and forms a
six member-chelate ring to each cobalt(II) and
copper(II) centers. The overall geometries of CoD
and CuD are a distorted octahedral and a

(b)
Figure 2. (a) CoD complex (b) CuD complex

distorted square pyramidal with water molecules
filling in the axial positions for the copper analogue.
The resulting structures have pseudo-layers that contain water molecules in between
these layers. This supramolecular effect arises from a combination of intermolecular π- π
stacking interaction between the phen ligands.
4.2) In vitro Cell Cytotoxicity
When S. cerevisiae demonstrated relative resistance towards both the copper dimer and
cobalt dimer complexes, but with little variations in MIC between the two (Table 1). According
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to the results, S. cerevisiae appears to be slightly more susceptible to copper than to the cobalt
analogue. This was expected because S. cerevisiae possess two copper import proteins, Ctr1 and
Ctr3.
When C. albicans isolate #1 was tested in RPMI media, CoD had MIC values between
0.977 and 1.9531 µg/mL while the copper dimer’s MIC was between 31.25 and 62.5 µg/mL
(Table 1). Based on the relative MIC values, C. albicans isolate #1 is 32-64 times more sensitive
to CoD than to CuD. When the KC643 WT (wildtype for the KC6 and KC7 crp1Δ mutants) was
tested in the same conditions, CoD demonstrated 32 to 128 times more activity than CuD with an
MIC range of 0.244 to 0.488 µg/mL for the CoD and 15.625 to 32.25 µg/mL for the CuD. The
maximum fluconazole control (maximally at 6.4 µg/mL) was found to be at 0.8 µg/mL for both
wildtype strains
C. albicans isolate #1 and KC643 WT were also tested in minimal YPD (lacking uridine)
media using the same assay procedures (Table 2). The results show that the yeast organisms
demonstrated higher tolerance towards CuD (MIC at 125-250 µg/mL) than towards CoD (MIC at
62.5 µg/mL). The MIC for the fluconazole control was 0.8 µg/mL. Interestingly, these strains
showed significantly enhanced growth in the minimal YPD media than in RPMI (Table 2 and 3).
The KC24 cup1Δ/ crp1Δ double gene knock-out mutant was tested in both RPMI and
minimal YPD media. In RPMI media, the cup1Δ/ crp1Δ mutant showed higher sensitivity
towards CuD than towards the CoD analogue (0.488 µg/mL and 3.125 µg/mL, respectively).
This was expected because the cup1Δ/ crp1Δ mutant lacked the caCRP1 and caCUP1 genes that
encode for the copper resistant mechanisms, metallothionein and P-type ATPase transporter
protein. This trend of decreased copper sensitivity is also seen when the cup1Δ/ crp1Δ mutant
was assayed in minimal YPD media. As was the case with wildtype KC643 and isolate #1, there
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was significantly more growth in YPD media than in RPMI with the fluconazole showing an
MIC value at 0.8 µg/mL instead of the 0.1 µg/mL in RPMI.

Organism

Isolate

Fluconazole (µg/mL)

CoD (µg/mL)

CuD (µg/mL)

Inoculum (10^3)

S. cerevisiae

0.4

3.906

1.953

4.95

S. cerevisiae

0.2

3.906

1.953

5.8

S. cerevisiae

0.8

3.906

1.953

5.1

CuD (µg/ mL)
31.25
62.5
62.5
31.25
62.5
15.625
31.25
0.488
0.977
15.625

Inoculum (103)
4.8
7.95
3
0.3
0.35
0.1
0.15
0.5
0.15
2.2

Table 1. MIC values of S. cerevisiae isolates in MHB

Organism
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans
C. albicans

Isolate
1
1
1
1
1
KC643 WT
KC643 WT
cup1Δ/ crp1Δ
cup1Δ/ crp1Δ
ATCC 90028

Fluconazole (µg/ mL)
0.1
0.1
0.1
0.1
0.025
0.05
0.05
0.1
0.1
0.2

CoD (µg/ mL)
0.977
1.953
0.977
0.977
0.977
1.953
0.244
3.125
0.244
4.883

Table 2. MIC values of C. albicans isolates in RMPI-MOPS

Organism

Isolate (-)

Fluconazole (µg/ mL)

CoD (µg/ mL)

CuD (µg/ mL)

Inoculum (103)

C. albicans

1

0.8/04

62.5

250

3.65

C. albicans

KC643 WT

0.8

62.5

62.5

0.9

C. albicans

KC643 WT

0.8

62.5

250

0.3

C. albicans

KC643 WT

0.8

62.5

125

3.6

C. albicans

KC643 WT

0.8

62.5

125

1.85

C. albicans

KC643 WT

0.8

(+)

31.25

2.6

C. albicans

KC643 WT

0.8

(+)

125

2.25

C. albicans

KC6 crp1Δ

0.8

(+)

62.5
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C. albicans

KC7 crp1Δ

0.8

(+)

62.5

1.55

C. albicans

cup1Δ/ crp1Δ

0.8

31.25

15.625

2.4

C. albicans

cup1Δ/ crp1Δ

0.8

125

15.625

2.5

Organism

Isolate (+)

Fluconazole (µg/ mL)

CoD (µg/ mL)

CuD (µg/ mL)

Inoculum (103)

C. albicans

KC12 WT

0.8

(+)

31.25

TBD

C. albicans

KC2 cup1Δ

0.8

(+)

31.25

TBD

Table 3. MIC values of C. albicans isolates in YPD (+)/(-) Uridine as indicated.
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Conclusion
Resistance to fluconazole by Candida albicans is a major issue for patients undergoing
long term treatment. C. albicans, as an opportunistic organism, provides several methods of
mutagenesis and offers great promise in deepening our understanding this yeast’s resistance. The
mutant strains that we used had homozygous URA3 disruptions. The URA3 disruption was
created by genetically transforming and selectively complimenting a gal1 mutation. The
subsequent recombination with a CAT sequence led GAL1 and one CAT copy to be excised.[13]
The mutant strains we used contained had the deletion and complementation of this
URA3 disruption, making the organisms dependent on outside sources of uridine, and were used
as quality control constructs. The wildtype KC2 (wildtype for mutants lacking the CaCUP1,
“cup1Δ”) lack the URA3 gene while the wildtype KC643 (wildtype for mutants lacking the
CaCRP1 gene, “crp1 Δ”) had the URA3 disrupted and recomplemented to ensure that the URA3
disruption itself did not have any effect on cell growth.[13]
Aside from fluconazole, studies by Kornitzer et al. have found that Candida albicans
demonstrated increased resistance against copper(II) metal. The CaCUP1 gene sequence is
identical to the protein sequence of C. albicans copper binding metallothionein and thus works
by chelating intracellular copper ions. The CaCRP1 gene has all the signature domains of copper
transporting ATPases, functions catalytically, and is therefore thought to play a more active role
in copper resistance. Of the two main copper mediators, CaCRP1 acts by effluxing copper while
the CaCUP1 functions stoichiometrically.[1]
MIC values obtained for the two wildtype strains and the Candida albicans isolate #1
shows that the CoD complex was consistently 32 to 62 times lower than the MIC values required
of the CuD. The KC643 WT also demonstrated marked sensitivity towards CoD with MIC 32 to
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132 times lower than the MIC values of CuD. Additionally, the double knockout mutants
(“cup1Δ /crp1Δ”) showed greater sensitivity towards the copper analogue than towards the
cobalt complex. This further suggested that CaCRP1 and/or CaCUP1 were responsible for the
higher resistance in the WT strains. However, according to table 3, CuD was more active in
cup1Δ /crp1Δ than in crp1Δ and cup1Δ alone. This suggests that metallothionein and the copper
extrusion pump are working together to reduce intracellular copper concentrations.
When in vitro assays were performed in YPD, overall increased growth of all the strains
was observed, especially in Candia albicans isolate #1 and the two wildtype strains. In these
three strains, higher MIC values were observed for CuD than for CoD, as expected, because all
three strains should still contain their copper resistance proteins. When comparing the growth
rates of the cup1Δ and crp1Δ mutants, it was found that the strains missing the CaCRP1 gene
was consistently more susceptible to the Cu(II) complex than to the CoD analogue. Additionally,
CuD was more active than CoD was in the cup1Δ /crp1Δ mutant. This suggests that both genes
function together for a greater total sum of copper resistance.
Another interesting observation is the lowered activity of CoD when in vitro assays were
performed in YPD media. The maximum CoD dimer solutions that were used contained both
25% and 2.5% methanol concentrations (drug vehicle control). Slight growth inhibition was
observed in 25% methanol, but the MIC values were comparable with those of the methanol
control that was also tested (data not shown) and no growth inhibition was seen in 2.5%
methanol. This observation is different from that seen when in vitro assays were performed in
RPMI media in which the CoD demonstrated substantially lower MIC values than its methanol
control. Along with decreased susceptibility towards CoD, the C. albicans strains also
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demonstrated lower MIC values for CuD, indicating a lower sensitivity to both CoD and CuD in
YPD media.
A possible explanation for the lowered susceptibility towards CuD and CoD in YPD
media could be that YPD contains metal chelators that in turn allows Candida albicans to grow.
This chelator effect is not observed in RPMI media or in MHB.
The MIC values observed for S. cerevisiae showed that the yeast is slightly more
sensitive to CuD than to CoD. Additionally, S. cerevisiae is more susceptible to CuD than was C.
albicans in RPMI assays. This observation aligned with our expectations because S. cerevisiae
possess two copper import transporters, Ctr1 and Ctr3. It is also possible that the actual substrate
for these transporters is Cu(I), suggesting that and Cu(II) is therefore reduced in the process.
Candida albicans contains a copper detoxification mechanism through an extensive
copper extrusion pump. However, at high copper concentrations, copper catalyzes reactive
oxygen species and is especially toxic in anaerobic conditions (such as in the digestive tract).
Therefore, in eukaryotes, intracellular copper concentration must be maintained through
controlling copper influx and the synthesis of copper chelators such as metallothionein.
It is likely that C. albicans’s ecological niche has led it to develop a dedicated resistant
mechanism. Candida albicans thrives in the digestive tract which contains the highest
concentration of copper. It was also found that copper becomes even more toxic in anaerobic
conditions, which is the case in the digestive tract. As a result, copper extruding pumps may have
developed through evolution to let Candida albicans survive in its environment. Acting alone,
the metallothionein would be unable to handle the amount of entering copper, leading to the
shutdown of the system. Therefore, Candida albicans likely adapted by developing a second
mechanism to pump out a continuous influx of copper: the P-type ATPases extrusion pump.[1]
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The observations of C. albicans growth in RPMI suggest that C. albicans does not have
similar resistance mechanisms for cobalt as it does for copper. In vitro assays of the Kornitzer
strains were discontinued in RPMI because minimal growth was seen all the microtiter plate
wells. However, observations of C. albicans in YPD media follows our expectations that the
mutant strains are more susceptible to copper due to the absence of a copper extrusion pump
and/or the copper binding protein, metallothionein.
Routes of investigation for the near future would be completing in vitro assays of all
strains as well as performing in vitro assays in MHB to determine if YPD contain metal binders.
Additionally, inductively coupled plasma atomic emission spectroscopy (ICP-AES) will be
performed to determine the metal retention time in all seven isolates of C. albicans.
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